The Shanghai Composite Index staged an afternoon recovery to close 0.19% higher on Tuesday, with advancing stocks outpacing decliners across the market. Total turnover on the Shanghai, Shenzhen, and Beijing exchanges reached 1.84 trillion yuan, contracting by 176.9 billion yuan from the prior session. Sector rotation remained brisk, with four key investment themes drawing particular attention.

First, the CXO sector experienced a powerful rally fueled by interim earnings releases. WUXI XDC surged 14.83% on the Hong Kong Stock Exchange to hit a yearly high, while Asymchem Laboratories (Tianjin) Co., Ltd. spiked 20% intraday in Hong Kong and hit the daily limit on its A-share listing. Second, the agriculture, forestry, and fishery segment resumed its upward momentum, with 金健米业, 万向德农, and 登海种业 all hitting their daily price ceilings. Third, fintech stocks rallied as the central bank expanded the roster of digital RMB operating institutions for the second time this year, bringing the total to 30, with all national banks now participating. Fourth, the chip sector received a triple boost from policy support, a turnaround in earnings for memory giant 佰维存储, and progress in the IPO of AI chip developer 燧原科技.

Market strategists see a range-bound recovery. CITIC Construction Investment Securities noted that while policy support provides a clear floor, the absence of concerted incremental capital inflows points to a continuation of the current stock-game dynamics, requiring stronger catalysts for a breakout above current levels. Everbright Securities suggested that the August earnings season could mark a pivotal shift from valuation digestion to earnings-driven gains, potentially offering the best allocation window for the second half of the year, supported by systemic policy backing and reduced sensitivity to overseas shocks.

For allocation, Everbright Securities recommends focusing on three earnings-driven themes: technology hardware (semiconductors, AI computing power, and memory), the price-increase chain (non-ferrous metals, chemicals, and coal) benefiting directly from PPI recovery, and export manufacturing (energy storage, power equipment, and automobiles) supported by global restocking and supply chain advantages. Additionally, the brokerage highlights improving fundamentals in non-bank financials, CROs within healthcare, and defense, suggesting a multi-pronged earnings landscape.

Delving into the CXO sector, the interim results season has reignited the rally. WUXI XDC soared 14.83% to a yearly peak, with WuXi Biologics and GenScript Biotech following suit. Asymchem surged 20% intraday in Hong Kong and locked in the daily limit on its A-share listing, while WuXi AppTec gained over 3% across both its A and H shares. Tigermed rose 5.95% in Hong Kong and 6.33% on the mainland. The HK-listed healthcare ETF (159137), with over 50% CXO exposure, traded robustly throughout the session, recording a bullish engulfing pattern on the daily chart and turnover of 247 million yuan—triple the previous day's volume and the highest in seven months.

The catalysts came from stellar interim reports. On August 24th, both WUXI XDC and Asymchem released their 2026 interim results, with adjusted net profits attributable to shareholders growing by 37.4% and 12.9% year-on-year, respectively. Order backlogs reinforce the sector's high prosperity: WUXI XDC's total outstanding orders reached $2.2 billion, up 62.2% year-on-year, while Asymchem's backlog stood at $1.673 billion, a 53.77% increase, with new orders growing 54.59%. WuXi AppTec reported an order backlog of 66.43 billion yuan, up 25.2%, and Pharmaron saw new orders surge over 30% in the first half.

Analysts suggest that a proactive restocking cycle in innovative drug outsourcing demand may have begun, confirming the fundamental uptrend. The Zheshang Securities healthcare team noted that order growth at CXO leaders exceeded expectations in the first half of 2026, reflecting a robust sector beta and high prosperity. They are optimistic about CXO stocks re-entering an accelerated order and earnings growth phase from 2026 onward, potentially even outpacing historical rates, and see the potential for a repeat of the epic 2019-2021 rally.

For investors seeking efficient exposure, the HK healthcare ETF (159137) tracks an index with over 50% CXO weighting, including more than 38% in WuXi-affiliated companies, offering high beta and T+0 trading. Its off-exchange feeder fund is 026922. The medical ETF (512170) covers eight CXO leaders with a combined weight exceeding 30%, with 25.624 billion yuan in AUM and average daily turnover of 675 million yuan; its feeder fund is 012323.

Turning to agriculture, the sector has regained its offensive stance amid mounting concerns over global food supply. 金健米业, 万向德农, and 登海种业 all hit daily limits, while 敦煌种业, 神农种业, and 华资实业 advanced over 6%. Meteorological agencies worldwide are converging on a stark outlook: the El Ni帽o phenomenon is expected to intensify in the second half of the year, with a 97% probability of persisting into early spring 2027, exacerbating global drought conditions. The chance of a strong El Ni帽o event between October and December is estimated at 81%, potentially ranking among the strongest since 1950.

The World Meteorological Organization's outlook also indicates that global average temperatures from 2026 to 2030 are likely to remain at or near historical highs, with extreme weather becoming the norm. Institutions warn that a fresh round of global food supply disruptions may be brewing, potentially erupting next year. Combined with potential geopolitical tensions in the Strait of Hormuz, a "super El Ni帽o" could drive up fertilizer and food prices, lifting global food inflation from 2.8% in the first half of 2026 to 5% by the first half of 2027.

Valuations in the sector remain relatively low, suggesting an opportune entry point. The CSI All-Share Agriculture, Forestry, and Fishery Index, tracked by the agribusiness ETF (159275), trades at a price-to-book ratio of 2.23 times, situated at the 6.27th percentile over the past five years. Sinolink Securities notes that amid external uncertainties, China's continued push for seed industry revitalization and higher grain yields, combined with global weather disruptions potentially reducing crop output, could improve the prosperity of the planting chain if actual production shortfalls materialize.

In the fintech space, digital RMB expansion has sparked a broad rally. 楚天龙 secured its third consecutive daily limit, 新晨科技 jumped over 16%, 艾融软件 gained more than 10%, and several other names advanced over 6%. Last week, the People's Bank of China added eight banks—including Ping An Bank, Evergrowing Bank, China Bohai Bank, Bank of Shanghai, Bank of Hangzhou, Huishang Bank, Bank of Changsha, and Guangxi Beibu Gulf Bank—as digital RMB operating institutions, expanding the total from 22 to 30.

This milestone is expected to accelerate the large-scale deployment of digital RMB in retail payments, corporate settlements, and government services, generating significant demand for system upgrades, hardware enhancements, and security encryption. It directly broadens the business horizons for fintech enterprises, presenting clear incremental market opportunities for core financial IT service providers. Guotai Haitong Securities observes that the AI-plus-finance trend remains intact, with short-term pullbacks creating buying opportunities. As AI agents permeate various industries, the fintech sector is entering a new phase of intelligent development with expansive growth potential.

From a valuation perspective, the fintech index remains over 39% below its peak from a year ago, with a dynamic price-to-earnings ratio of 43 times—situated at the 13th percentile over three years—indicating a historically low valuation. The fintech ETF (159851) and its feeder funds (013477 for A-class, 013478 for C-class) offer exposure to internet brokerages, financial IT, cross-border payments, and AI applications, combining financial cyclicality with tech growth attributes.

Investors are reminded that market volatility may remain elevated, and short-term performance does not predict future results. All investment decisions should be based on individual financial circumstances and risk tolerance, with careful attention to position and risk management.